Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genes
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Grant support
CA103314
NCI NIH HHS - United States
- MeSH
- Cytochrome P-450 CYP3A genetics MeSH
- Rats MeSH
- Lymphoma drug therapy metabolism pathology MeSH
- Membrane Proteins genetics MeSH
- ATP Binding Cassette Transporter, Subfamily B genetics MeSH
- Neovascularization, Pathologic genetics MeSH
- Area Under Curve MeSH
- Rats, Sprague-Dawley MeSH
- Antineoplastic Agents blood pharmacology therapeutic use MeSH
- Gene Expression Regulation, Neoplastic drug effects MeSH
- Taxoids blood pharmacology therapeutic use MeSH
- Tumor Burden drug effects MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, N.I.H., Extramural MeSH
- Names of Substances
- Cyp3a2 protein, rat MeSH Browser
- Cyp3a23-3a1 protein, rat MeSH Browser
- Cytochrome P-450 CYP3A MeSH
- Membrane Proteins MeSH
- multidrug resistance protein 3 MeSH Browser
- ATP Binding Cassette Transporter, Subfamily B MeSH
- Antineoplastic Agents MeSH
- Taxoids MeSH
The study investigated possible mechanisms by which second-generation taxanes, established as significantly more effective than paclitaxel in vitro, suppress a rat lymphoma model in vivo. The studied mechanisms included taxane pharmacokinetics, expression of genes dominating their metabolism (Cyp3a1/2) and transport (Abcb1) and genes controlling tumour angiogenesis (growth factors and receptors). SB-T-1214, SB-T-12854 and IDN5109 suppressed rat lymphoma more effectively than paclitaxel, SB-T-12851, SB-T-12852, SB-T-12853 or IDN5390 as well as P388D1 leukaemia cells in vitro. The greater anti-lymphoma effects of SB-T-1214 in rats corresponded to a higher bioavailability than with SB-T-12854, and lower systemic toxicity of SB-T-1214 for rats reflected its lower cytotoxicity for P388D1 cells in vitro. Suppression of Abcb1 and CYP3a1 expression by SB-T-1214 and IDN5109 could partly explain their anti-lymphoma effects, but not that of SB-T-12854. Growth factors genes Egf, Fgf, Pdgf, and Vegf associated with tumour angiogenesis had significantly lower expression following treatment with anti-lymphoma effective IDN5109 and their receptors were unaffected, whereas inefficient IDN5390 increased expression of the most important Vegf. The effective SB-T-12854 inhibited Egf, Egfr, Fgfr and Pdgfr expression, while the ineffective SB-T-12851, SB-T-12852 and SB-T-12853 inhibited only Egf or Egfr expression. Vegfr expression was inhibited significantly by SB-T-12851 and SB-T-12854, but effect of SB-T-12851 was compromised by induced Vegf expression. The very effective SB-T-1214 decreased the expression of Vegf, Egf and all receptors most prominently indicating the possible supporting role of these genes in anti-lymphoma effects. In conclusion, SB-T-1214, SB-T-12854 and IDN5109 are good candidates for further study.
See more in PubMed
Endothelium. 2008 Jan-Feb;15(1):9-15 PubMed
Invest New Drugs. 2010 Dec;28 Suppl 1:S58-78 PubMed
Folia Biol (Praha). 2002;48(6):213-26 PubMed
Eur J Pharm Sci. 2006 Dec;29(5):442-50 PubMed
Cancer Res. 2005 Mar 15;65(6):2397-405 PubMed
Bull Cancer. 2010 Apr;97(4):E23-32 PubMed
Clin Cancer Res. 2002 Apr;8(4):1182-8 PubMed
Clin Pharmacol Ther. 2003 Oct;74(4):364-71 PubMed
Toxicol Lett. 2010 Jul 1;196(2):74-9 PubMed
Exp Cell Res. 2006 Mar 10;312(5):549-60 PubMed
Xenobiotica. 2006 Sep;36(9):772-92 PubMed
Cancer Lett. 2005 Apr 18;221(1):105-18 PubMed
Arch Toxicol. 2000 Oct;74(8):437-46 PubMed
Invest New Drugs. 2011 Jun;29(3):411-23 PubMed
Pharmacogenet Genomics. 2008 Mar;18(3):263-73 PubMed
Trials. 2010 May 25;11:62 PubMed
Clin Cancer Res. 2001 Dec;7(12):4156-63 PubMed
J Oncol Pharm Pract. 2011 Sep;17(3):179-85 PubMed
Cancer Chemother Pharmacol. 1989;24(3):148-54 PubMed
Anticancer Res. 2000 Mar-Apr;20(2A):1041-7 PubMed
J Med Chem. 1997 Jan 31;40(3):267-78 PubMed
Acc Chem Res. 2008 Jan;41(1):108-19 PubMed
Anticancer Res. 2005 Nov-Dec;25(6B):4215-24 PubMed
J Chem Inf Model. 2009 Feb;49(2):424-36 PubMed
Oncol Rep. 2006 Feb;15(2):329-34 PubMed
ChemMedChem. 2007 Jul;2(7):920-42 PubMed
Stem Cells. 2005 Oct;23(9):1417-22 PubMed
J Med Chem. 1996 Sep 27;39(20):3889-96 PubMed
Cell Mol Life Sci. 2006 Mar;63(5):601-15 PubMed
Naunyn Schmiedebergs Arch Pharmacol. 2005 Jul;372(1):95-105 PubMed
Clin Cancer Res. 2002 Aug;8(8):2647-54 PubMed
Anticancer Res. 2009 Aug;29(8):2951-60 PubMed
J Natl Cancer Inst. 2001 Aug 15;93(16):1234-45 PubMed
J Med Chem. 2008 Jun 12;51(11):3203-21 PubMed
Nature. 2000 Sep 14;407(6801):249-57 PubMed
Crit Rev Oncol Hematol. 2007 May;62(2):105-18 PubMed
Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216
